In ATLL, the median OS for CD5+ patients was 9.7 months (95% CI: 0.93 months—15.2 months) vs. 82.7 months (56.7 months-103.3 months) in the CD5- arm. Here, CD5 is linked to adult T-cell leukemia/lymphoma.